TMC reported a net loss of $109.6 million for the fourth quarter of 2022, with cash holdings of $46.8 million and no debt. The loss was primarily driven by increased exploration and evaluation expenses related to Allseas warrants and share issuances.
TMC held cash of $46.8 million and had no debt as of December 31, 2022.
The company reported a net loss of $109.6 million for Q4 2022, or $0.41 per share.
Exploration and evaluation expenses increased to $104.3 million due to Allseas warrants and share issuances.
A non-binding MOU was signed with PAMCO of Japan to evaluate nodule processing.
TMC continues to hit milestones and establish the strategic partnerships to continue delivering on our capital-light approach to developing the NORI-D Nodule Project.